Patritumab deruxtecan
Daiichi Sankyo · Merck & Co. · U3-1402 · HER3-DXd
FollowEvery change as it happens, and a Monday email
Trials
16 active
18 in total · 13 in the EU
What this is
- How it works
- HER3-targeted antibody-drug conjugate
- How it’s given
- “Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.”In the company’s words, NCT04619004 on ClinicalTrials.gov
- Tested for
- Breast Neoplasms (3 trials), Breast Cancer (3 trials), Non-small Cell Lung Cancer (NSCLC) (3 trials), Gastroesophageal Junction (2 trials), Gastroesophageal Adenocarcinoma (2 trials), Esophageal Neoplasms (2 trials), Esophageal Cancer (2 trials), Nonsquamous Non-small Cell Lung Cancer and 24 more
- Main trialPhase 3
- “Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile. There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggests that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.”In the company’s words, NCT05338970 on ClinicalTrials.gov
- Other names
- U3-1402 · HER3-DXd
Other drugs for Breast Neoplasms
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up12
- 9 May 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 7 Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 17 Aug 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 12 Sep 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Dec 2029Phase 2 trial completes · ClinicalTrials.gov
- 19 Nov 2030Phase 2 trial completes · ClinicalTrials.gov
- 30 Dec 2030Phase 1/2 trial completes · ClinicalTrials.gov
- 1 Jan 2031Phase 1/2 trial completes · ClinicalTrials.gov
- 13 Feb 2032Phase 1/2 trial completes · ClinicalTrials.gov
- 12 Mar 2032Phase 2 trial completes · ClinicalTrials.gov
- 2 Aug 2032Phase 1/2 trial completes · ClinicalTrials.gov
- 14 Jul 2033Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovCompletion date moved: 2027-09-01 to 2030-11-19 · ClinicalTrials.gov NCT06172478
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 May 2024 | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | |
| Phase 3Recruiting | 14 Jul 2033 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | |
| Phase 2Active, not recruiting | 21 Nov 2022 | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | |
| Phase 2Recruiting | 31 Dec 2029 | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | |
| Phase 2Recruiting | 19 Nov 2030 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | |
| Phase 2Recruiting | 12 Mar 2032 | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | |
| Phase 1/2Recruiting | 9 May 2028 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | |
| Phase 1/2Active, not recruiting | 7 Dec 2028 | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | |
| Phase 1/2Recruiting | 17 Aug 2029 | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | |
| Phase 1/2Recruiting | 12 Sep 2029 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | |
| Phase 1/2Recruiting | 30 Dec 2030 | A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | |
| Phase 1/2Recruiting | 1 Jan 2031 | A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer | |
| Phase 1/2Recruiting | 13 Feb 2032 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | |
| Phase 1/2Recruiting | 2 Aug 2032 | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | |
| Phase 1Active, not recruiting | 31 Jan 2025 | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | |
| Phase 1Active, not recruiting | 1 Dec 2025 | U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | |
| Phase 2Terminated | 3 Feb 2022 | A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer | |
| Phase 1/2Completed | 16 Aug 2021 | Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026